HLS Therapeutics Inc

View in Terminal

Loading quotes...

Forecast

Buy	0
Hold	1
Sell	0

News Go to news feed

There is currently no news available for this company. We are working on adding more providers to change this.

Historical dividends Dividends

All dividend metrics All metrics

In 2023, HLS Therapeutics Inc has already paid €0.0688 in dividends. The last payout was in June 2023.

Financials

In the last quarter, HLS Therapeutics Inc had revenue of €12.86m and net profit of -€893.73k

(EUR)	June 2026	YoY
Revenue	12.86m	6.93%
Gross profit	10.36m	4.64%
Net profit	-893.73k	61.57%
EBITDA	4.61m	15.32%

Fundamentals

Metric	Value
Market capitalization	€86.72m
Number of shares	30.94m
52-week high/low	€3.58 - €2.35
Dividends	No
Beta	0.82
P/E ratio	-11.85
PEG ratio	-0.19
P/B ratio	1.94
P/S ratio	1.73

Company profile

HLS Therapeutics Inc., a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular (CV) markets in Canada, the United States, and internationally. The company's product portfolio includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsules; and PERSERIS, an injectable risperidone product for the treatment of schizophrenia. It also offers MyCare psychiatry lab assays and MyCare Insite point of care therapeutic drug-level monitoring tests. In addition, the company holds the U.S. marketing rights of Absorica, a commercial stage dermatology product; Canadian rights of Trinomia for CV therapeutics; and a portfolio of royalty interests of four healthcare products. HLS Therapeutics Inc. was founded in 2018 and is headquartered in Etobicoke, Canada.